{"id":"NCT02194985","sponsor":"Amicus Therapeutics","briefTitle":"Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease","officialTitle":"An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-14","primaryCompletion":"2019-10-23","completion":"2019-10-23","firstPosted":"2014-07-21","resultsPosted":"2020-12-21","lastUpdate":"2020-12-21"},"enrollment":84,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"DRUG","name":"migalastat HCl 150 mg","otherNames":["AT1001","Galafold"]}],"arms":[{"label":"Migalastat HCl 150 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.","primaryOutcome":{"measure":"Number Of Participants Experiencing Adverse Events (AEs)","timeFrame":"Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years","effectByArm":[{"arm":"Migalastat HCl 150 mg","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":28,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Denmark","Egypt","France","Italy","Japan","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31889231"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":84},"commonTop":["Nasopharyngitis","Fatigue","Arthralgia","Pain in extremity","Paraesthesia"]}}